

ASX ANNOUNCEMENT

KEY ANTIBODY PATENT GRANTED IN JAPAN

- **Japanese patent for treating autoimmune disorders using midkine antibodies granted**
- **Novel mechanism of action boosting regulatory T cells**
- **USA patent already granted in 2012**

SYDNEY, Friday, 18 October 2013: Cellmid Limited (ASX: CDY) advises that the Japanese Patent Office (JPO) granted Cellmid's patent application JP 2007-544236 "Method for Treatment or Prevention of Diseases Associated with a Functional Disorder of Regulatory T Cells".

JP 2007-544236 is a member of a key patent family in Cellmid's antibody patent portfolio. Its grant adds yet another layer of intellectual property protection to Cellmid's anti-midkine antibody (MK antibody) programme.

JP 2007-544236 covers the use of MK antibodies to increase the number of regulatory T cells (Tregs). Tregs are central controllers of autoimmune responses; when Treg numbers are too low, the body's immune system can attack its own tissues, leaving subjects vulnerable to autoimmune diseases. Increasing the Treg numbers can mitigate such autoimmune attack.

Published studies show that midkine suppresses Treg numbers, but Treg numbers can be boosted by the use of MK antibodies. In animal models of autoimmunity, inhibiting midkine using Cellmid's MK antibodies alleviated disease.

The USA patent in this family was granted last year (Cellmid, ASX Announcement 07 May 2012), with similar claims allowed. The patents in this family expire in 2027.

An updated figure in relation to the Company's extensive patent protection around MK antibodies is included below. The coloured sectors indicate areas in which patents have been granted. The figure also marks the recent granting of Cellmid's patents for C-terminal binding antibodies.

End

Contact:


Maria Halasz, CEO

T +612 9221 6830



@mariahalas

Figure 1: Cellmid's anti-midkine antibody patents provide multilayered protection for the Company's antibody programs including composition, mechanism of action and method of use.



Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced development programs involve using its anti-midkine antibodies for the treatment of cancer and inflammatory diseases. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. For further information please see www.cellmid.com.au.

Midkine (MK)

Midkine is a multifunctional growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, because midkine is only present in a disease context, targeting midkine does not harm normal healthy tissues.